Iterum Therapeutics (NASDAQ:ITRM) had its price objective reduced by Royal Bank of Canada to $17.00 in a report published on Wednesday, The Fly reports. They currently have an outperform rating on the stock.
ITRM has been the subject of several other reports. Zacks Investment Research lowered Iterum Therapeutics from a hold rating to a sell rating in a report on Wednesday, February 6th. Needham & Company LLC restated a buy rating and issued a $20.00 target price on shares of Iterum Therapeutics in a report on Monday, March 25th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $17.00.
Shares of Iterum Therapeutics stock traded up $0.01 during trading on Wednesday, hitting $7.26. 898 shares of the stock traded hands, compared to its average volume of 10,580. The firm has a market cap of $101.21 million and a price-to-earnings ratio of -1.02. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.61 and a quick ratio of 7.61. Iterum Therapeutics has a twelve month low of $4.70 and a twelve month high of $13.00.
About Iterum Therapeutics
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Recommended Story: Put Option
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.